#USA #Brooklyn #Sanfilippo Syndrome #Phoenix Nest #JLK-247

Phoenix Nest Awarded Significant SBIR Grant

Phoenix Nest, a biotech company rooted in patient advocacy and scientific innovation, has received a substantial boost in their mission to combat Sanfilippo syndrome type C. The company has recently been awarded a $2,984,658 grant from the Small Business Innovation Research (SBIR) program, which will focus on manufacturing clinical-grade gene therapy products designed to treat this rare and devastating childhood disease.

This grant, designated as R44NS147802, marks a significant milestone for Phoenix Nest and the families it serves. The funding will primarily support the manufacturing of the AAV9 gene therapy, referred to as JLK-247. This therapy represents a groundbreaking step toward treating and potentially curing children afflicted with Sanfilippo syndrome, also known as Mucopolysaccharidosis type III (MPS III).

Advancements in Gene Therapy

The lead advocate for the company, Jill Wood, who is not only the CEO but also a parent of a child diagnosed with MPS IIIC, expressed immense gratitude towards the National Institute of Neurological Disorders and Stroke (NINDS) for their continued support. “Thank you to NINDS leadership and NIH reviewers for believing in our program over the years. This newly awarded grant brings us closer to delivering therapy to patients,” she stated.

Currently, Phoenix Nest is actively recruiting patients for their natural history study, which takes place at the University of Texas at Southwestern (UTSW) in Dallas, TX. The research is pivotal, as it works to gather essential data on the progression of Sanfilippo syndrome in children, further supporting the need for effective treatments.

Regaining Hope for Families

JLK-247 has received both orphan drug designation and rare pediatric disease designation from the FDA, reflecting the urgency and necessity of developing this treatment. With the support of numerous patient organizations and NIH SBIR grants, Phoenix Nest aims to provide improvement in the quality of life for children battling this debilitating condition.

Additionally, Phoenix Nest has created a unique application known as C-RARE, designed to capture and record the daily living experiences and functional capacities of children with MPS IIIC. This innovative approach not only aids in understanding the impact of the disease but also strengthens the case for commercializing the therapy once available.

The recent identification of Heparan Sulfate as a surrogate biomarker heralds another positive note in Phoenix Nest's journey, offering insights into patient responses to the treatments and aiding the pharmaceutical development process.

Inspired by Patient Advocacy

Founded by a collective of caregivers and scientists, Phoenix Nest embodies the spirit of perseverance and innovation. The company’s narrative is inspired by the mythical Phoenix, a creature known for rising from its ashes and representing hope and resilience. Just as the Phoenix builds its nest with healing herbs, Phoenix Nest reflects the dedication of parents striving to provide effective treatments for their children.

The support from various organizations, including the Columbus Children's Foundation, the Cure Sanfilippo Foundation, the International Sanfilippo Syndrome Alliance, and others has further fueled their mission. As Phoenix Nest continues to forge ahead with their research and development efforts, the urgency to combat Sanfilippo syndrome type C cannot be overstated.

In conclusion, the awarded SBIR grant serves as a beacon of hope for not just the company, but for families dreaming of better lives for their children suffering from this rare and fatal childhood disease. The collaborative efforts between scientists, healthcare professionals, and advocacy groups pave the way for a future where treatments and cures may finally be within reach.